NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVB and the CUSIP is 63937X202. A total of 33 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $900 | -2.6% | 10,043 | 0.0% | 0.00% | – |
| Q2 2023 | $924 | -64.6% | 10,043 | 0.0% | 0.00% | – |
| Q1 2023 | $2,611 | -96.3% | 10,043 | -50.0% | 0.00% | -100.0% |
| Q4 2022 | $70,552 | +1173.0% | 20,086 | -0.1% | 0.00% | – |
| Q3 2022 | $5,542 | -23.4% | 20,100 | +100.0% | 0.00% | – |
| Q2 2022 | $7,236 | -9.6% | 10,050 | 0.0% | 0.00% | – |
| Q1 2022 | $8,000 | -20.0% | 10,050 | 0.0% | 0.00% | – |
| Q4 2021 | $10,000 | -41.2% | 10,050 | 0.0% | 0.00% | – |
| Q3 2021 | $17,000 | -5.6% | 10,050 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $18,000 | -10.0% | 10,050 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $20,000 | -9.1% | 10,050 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $22,000 | -21.4% | 10,050 | 0.0% | 0.00% | -66.7% |
| Q3 2020 | $28,000 | -28.2% | 10,050 | 0.0% | 0.00% | -40.0% |
| Q2 2020 | $39,000 | +387.5% | 10,050 | 0.0% | 0.01% | +400.0% |
| Q1 2020 | $8,000 | -93.7% | 10,050 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $127,000 | +2440.0% | 10,050 | +33.6% | 0.00% | 0.0% |
| Q3 2019 | $5,000 | 0.0% | 7,525 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $5,000 | – | 7,525 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Allred Capital Management, LLC | 466,688 | $41,862 | 0.02% |
| Warberg Asset Management LLC | 194,997 | $17,491 | 0.00% |
| Virtu Financial LLC | 333,069 | $30 | 0.00% |
| UBS Group AG | 149,612 | $13,466 | 0.00% |
| NewEdge Advisors, LLC | 412 | $36 | 0.00% |
| Parallel Advisors, LLC | 350 | $31 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 1,604 | $143 | 0.00% |
| WELLS FARGO & COMPANY/MN | 5,632 | $504 | 0.00% |
| NORTHERN TRUST CORP | 39,414 | $3,535 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |